These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23138542)

  • 1. Electron-microscopy of cherry haemangioma in the early diagnosis of Fabry disease.
    Tokuriki A; Kiyohara T; Kumakiri M
    Acta Derm Venereol; 2013 Jul; 93(4):471-2. PubMed ID: 23138542
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
    Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
    [No Abstract]   [Full Text] [Related]  

  • 3. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
    Martin-Suárez I; Suárez-Marrero C
    Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
    [No Abstract]   [Full Text] [Related]  

  • 4. Fabry disease: is there a role for enzyme replacement therapy?
    Mehta AB
    J Intern Med; 2013 Oct; 274(4):329-30. PubMed ID: 23662843
    [No Abstract]   [Full Text] [Related]  

  • 5. Enzyme replacement therapy for Fabry's disease.
    Waldek S; Germain DP; Wanner C; Warnock DG
    Lancet; 2010 May; 375(9725):1523; author reply 1523-4. PubMed ID: 20435225
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiokeratomas and treatment with enzyme replacement therapy in a patient with Fabry disease.
    Merzel Šabović EK; Žerjav Tanšek M; Grošelj U; Dragoš V
    Acta Dermatovenerol Alp Pannonica Adriat; 2020 Jun; 29(2):89-91. PubMed ID: 32566958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy for Fabry's disease.
    Deegan P
    Lancet; 2010 May; 375(9725):1522-3; author reply 1523-4. PubMed ID: 20435224
    [No Abstract]   [Full Text] [Related]  

  • 8. [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
    Lidove O; Choukroun G; Bekri S; Viot G; Tsimaratos M; Joly D
    Presse Med; 2010 May; 39(5):527-9. PubMed ID: 20194001
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry's disease.
    Hirashio S; Taguchi T; Naito T; Maki K; Ogata S; Taniyama K; Taniguchi Y; Yorioka N
    Clin Nephrol; 2009 May; 71(5):550-6. PubMed ID: 19473616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease: dose matters.
    Warnock DG; Mauer M
    J Am Soc Nephrol; 2014 Apr; 25(4):653-5. PubMed ID: 24556355
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
    Lenders M; Brand E
    J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Utility of enzyme replacement therapy in Fabry disease].
    Politei JM; Dubrovsky A
    Med Clin (Barc); 2010 Apr; 134(9):402-5. PubMed ID: 20138313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

  • 16. Enzyme replacement in Anderson-Fabry disease.
    Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
    Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
    [No Abstract]   [Full Text] [Related]  

  • 17. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
    Banikazemi M; Desnick RJ
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
    [No Abstract]   [Full Text] [Related]  

  • 18. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
    Wanner C
    Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
    Hollak CE; Linthorst GE
    Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
    del Toro N; Milán JA; Palma A
    Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.